DEICCHE ADDITION DECLARATION DE			
REISSUE APPLICATION DECLARATION BY TH	E ASSIGNEE Docket Number: 5/891-1-C1 Reissue		
We hereby declare that: My residence, post office address and citizenship are stated below next to my name. We are authorized to act on behalf of the following company: Dr. Karl Thomae GmbH and the title of my position with said company is: The entire title to the patent identified below is vested in said company.			
Name of Patentee: Wolfgang GRELL, Rudolf HURNAL	JS, Gerhart GRISS (By Elizabeth GRISS, Executrix).		
Robert SAUTER, Manfred REIFFEN and Eckhard RUPPRECHT			
Patent Number: 5,216,167	Date Patent Issued: June 1, 1993		
Title of Invention: PHENYLACETIC ACID BENZYLA	MIDES		
We believe said patentee to be the original, first and sole described and claimed in said patent, for which a reissper PHENYLACETIC ACID BENZYLAMIDES			
the specification of which			
is attached hereto.	ADEMARK!		
was filed on October 7, 1997, as reissue application and was or will be amended on .			
We have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.			
We acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.			
We verily believe the original patent to be wholly or partly inoperative or invalid, for the reasons described below. (Check all boxes that apply.)			
by reason of a defective specification or drawing, said defects being described below.			
by reason of the patentee claiming more or less that he had the right to claim in the patent, said excess or insufficiency in the claims being specified below.			
by reason of other errors, described below.			
The errors relied upon in the above statement, and how the errors occurred, are as follows:			
The terminal disclaimer filed on August 6, 1992, in connection with U.S. Serial No. 07/495,820, the application from which U.S. patent No. 5,216,167 issued, disclaimed only the term of any patent issuing from that application subsequent to October 10, 2006, <i>i.e.</i> , the expiration date of U.S. patent no. 4,873,080. However, both U.S. patent nos. 4,873,080 and 4,863,724 are co-owned by assignee Dr. Karl Thomae GmbH, and both disclose and claim subject matter relating to repaglinide. Thus, in an abundance of caution, the assignee believes that U.S. patent no. 5,216,167 should be terminally disclaimed over both U.S. patent nos. 4,873,080 and 4,863,724. Accordingly, a terminal disclaimer which disclaims the term of U.S. patent no. 5,216,167 subsequent September 5, 2006, <i>i.e.</i> , the expiration date of U.S. patent no. 4,863,724, is submitted berewith			

(REISSUE APPLICATION DECLARATION BY THE ASSIGNEE, page 2)			Docket No.: 5/891-1-C1 Reissue		
The errors described above arose without any deceptive intention on the part of the applicant.					
I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the patent and Trademark Office connected therewith.					
Name(s) Robert P. Raymond Mary-Ellen M. Devlin Alan R. Stempel Anthony P. Bottino	n		Registration N 25,089 27,928 28,991 41,629	ło.:	· .
Correspondence Add	ress: Direct all communication	s about the a	pplication to:		:
Customer Number	er	>	Place Customer Number Bar Code		7
OR	Type Customer Number Her	e	Label here		
Firm or Individual Name	Robert P. Raymond		,	·	
Address	c/o Boehringer Ingelheim Corp. 900 Ridgebury Road				
Address					
City	Ridgefield	State	CT	Zip	06877
Country	US				
Telephone	203-798-4864	Fax	203-791-6183		
We, representing the	assignee, hereby consent to the	filing of a re	eissue application.		
We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine and imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this declaration is directed.					
Full name of person s name)	signing (given name, family	Full name)	me of person signing	(given nam	e, family
Signature ppa.		Signatu ppa.	ire		
Date		Date			
Residence		Resider	nce		
Citizenship:		Citizen	ship:		
Post Office Address		Post Of	ffice Address		
<u>•</u>		Citizen	ship:		

(Page 2 of 2)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it displays a valid OMB control number.

REISSUE APPLICATION DECLARATION BY THE INVENTOR

Docket Number (Optional) 5/891-1-C1 Reissue

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is described and claimed in patent number 5,216,167, granted June 1, 1993, and for which a reissue patent is sought on the invention entitled:

PHENYLACETIC ACID BENZYLAMIDES

the specification of which

is attached hereto

was filed on October 7, 1997, as reissue application number 08/946,602 and was or will be amended on (if applicable)

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability is defined in 37 CFR 1.56.

I verily believe the original patent to be wholly or partly inoperative or invalid, for the reasons described below. (Check all boxes that apply.)

	by reason of a defective specification or drawing.
\boxtimes	by reason of the patentee claiming more or less that he had the right to claim in the patent.
	by reason of other errors.

At least one error upon which reissue is based is described as follows:

The terminal disclaimer filed on August 6, 1992, in connection with U.S. Serial No. 07/495,820, the application from which U.S. patent No. 5,216,167 issued, disclaimed only the term of any patent issuing from that application subsequent to October 10, 2006, *i.e.*, the expiration date of U.S. patent no. 4,873,080. However, both U.S. patent nos. 4,873,080 and 4,863,724 are co-owned by assignee Dr. Karl Thomae GmbH, and both disclose and claim subject matter relating to repaglinide. Thus, in an abundance of caution, the assignee believes that U.S. patent no. 5,216,167 should be terminally disclaimed over both U.S. patent nos. 4,873,080 and 4,863,724. Accordingly, a terminal disclaimer which disclaims the term of U.S. patent no. 5,216,167 subsequent September 5, 2006, *i.e.*, the expiration date of U.S. patent no. 4,863,724, is submitted herewith.

(Page 1 of 3)

Burden Hour Statement: This form is estimated to take 0.5 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Office, Patent and Trademark Office, Washington, DC 20231.

PTO/SB/51 (12-97)
Approx for use through 9/30/00. OMB 0651-0033
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it displays a valid OMB control number.

(REISSUE APPLICA	TION DECLARATION BY THE I	NVENTOR, page		Jocket Num 5/891-1-C1	iber (Optional) Reissue	
All errors corrected in this reissue application arose without any deceptive intention on the part of the						
applicant. As a nam	ned inventor, I hereby appoint the	e following attor	ney(s) and	l/or agenti	(s) to prosecute	
this application and	transact all business in the Paten	t and Trademark	Office co	nnected t	herewith.	
N I(-)	_					
Name(s)		gistration Number	er			
Dr. Robert P. Raymo		7 7 7	E			
Mary-Ellen M. Devl			~ <u>~</u> ~			
Alan R. Stempel	28,9		س 1999 4		100-	
Anthony P. Bottino	41,0	529 Ark 1	- 1000 B			
Correspondence Address	s: Direct all communications about the	application (A)	ADEMPRE CO			
Customer Number			•			
_			ustomer Nui ibel here	nber Bar		
<u>OR</u>	Type Customer No. here					ļ
Firm or						_
Individual Name	Boehringer Ingelheim Corpora	tion				
	Attn: Dr. R.P. Raymond					
Address	900 Ridgebury Road, P.O. Box	: 368				_
Address	7 00 1110g0000, 11000, 1101, 201					_
City	Ridgefield	State	CT	ZIP	06877-0368	_
Country	US	1	1 0 1		1 000,, 0000	_
Telephone	203-798-4866	FAX	203-791	-6183		
•	t all statements made herein of m				all statements	_
	n and belief are believed to be tru					
	willful false statements and the li					
	S.C. 1001, and that such willful					,
	ent issuing thereon, or any patent					
	inventor (given name, family name)					_
Wolfgang GRELL						
Inventor's signature						
Residence		Date				
Post Office Address		Citizenship				
Full name of second or joint inventor (given name, family name)						
Ruldolf HURNAUS						
Inventor's signature						
Residence		Date		·		
Post Office Address		Citizenship	•			
Full name of third or joint inventor (given name, family name) Gerhart GRISS (By Elizabeth GRISS, Executrix)						
Inventor's signature						
Residence		Date				_
Post Office Address		Citizenship				
Additional joint inventors are named on separately numbered sheets attached hereto.						

(REISSUE APPLICATION DECLARATION BY THE INVENTOR, page 3)		Docket Number (Optional) 5/891-1-C1 Reissue
Full name of sole or first inventor (given name, family name)		
Robert SAUTER		
Inventor's signature	Date	
Residence	Citizenship	
Post Office Address		
Full name of second or joint inventor (given name, family name)		
Manfred REIFFEN		
Inventor's signature	Date	····
Residence	Citizenship	
Post Office Address		
Full name of third or joint inventor (given name, family name) Eckhard RUPPRECHT		
Inventor's signature	Date	
Residence	Citizenship	
Post Office Address		
Additional joint inventors are named on separatel	y numbered sheets at	tached hereto.